steroid betamethasone

Phase 1Small molecule

CCairo University

steroid betamethasone is one of 23 small molecule programs targeting Hypospadias. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypospadiasActive, not recruiting

HypospadiasPhase 1

Active, not recruiting

Competition

Competitive Landscape

35 competitors in Hypospadias

#DrugCompanyPhaseTrials

Decadron

AAspen Global Incorporated

Approved

3 2

Adrenaline

SSamson Clinical Operations Pty Ltd

Approved

1 3

Ketalar

AAultman Health Foundation

Approved

1 4

Naropin

FFresenius Kabi Oncology Ltd.

Approved

1 5

Celestone

Advil

Tylenol

Oxycontin

Atropen

FFresenius Kabi Oncology Ltd.

Marcaine

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hypospadias1 trial

The Role of Local Long Acting Corticosteroid Injection in Hypospadias Surgery.

Unknown status·—·Phase 1·NCT04196400·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for steroid betamethasone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — steroid betamethasone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for steroid betamethasone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cairo University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: CCairo University

steroid betamethasone

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hypospadias1 trial

References

Drug Info

Quick Facts

Related News